Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revolution Medicines Buyback Yield % Related Terms
Revolution Medicines Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Revolution Medicines's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1RVMD vs ALNY, ONC, MRNA: Buyback Yield % Comparison
For the Biotechnology subindustry, Revolution Medicines's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revolution Medicines Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revolution Medicines's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Revolution Medicines's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines (MIL:1RVMD) has a Buyback Yield % of -0.57 as of Jul. 19, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Revolution Medicines and its competitors. According to the industry distribution chart, Revolution Medicines ranks #186 out of 740 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Revolution Medicines' Buyback Yield % too high?
Revolution Medicines' current Buyback Yield % is -0.57. Based on the distribution chart, Revolution Medicines ranks #186 out of 740 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Revolution Medicines has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' Buyback Yield % compare to ALNY and ONC?
According to the Biotechnology industry distribution chart, Revolution Medicines ranks #186 out of 740 companies for Buyback Yield %. This puts Revolution Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current Buyback Yield % is -0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Based on GuruFocus' analysis, Revolution Medicines (MIL:1RVMD) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.40, compared to a current price of €160.15 — trading 39937.5% above its estimated fair value. The current Buyback Yield % is -0.57. Revolution Medicines' overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Revolution Medicines (MIL:1RVMD), the current Buyback Yield % is -0.57 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revolution Medicines (MIL:1RVMD) Overvalued in 2026?
Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued.
The current stock price of €160.15 is trading 39937.5% above its estimated GF Value™ of €0.40.
GuruFocus considers Revolution Medicines to be Significantly Overvalued.
Key valuation signals for MIL:1RVMD:
Buyback Yield %: -0.57
GF Value™: €0.40 vs. price of €160.15 (39937.5% above fair value)
No single metric tells the full story. See the MIL:1RVMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
9GF Score
Get the complete analysis for MIL:1RVMD
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1RVMD has been successfully added to your 
